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Our current knowledge of the molecular mechanisms
regulating the signaling pathways leading to cell survival, cell
death, and inﬂammation has shed light on the tight mutual
interplays between these processes. Moreover, the fact that
both apoptosis and necrosis can be molecularly controlled
has greatly increased our interest in the roles that these types
of cell death play in the control of general processes such as
development, homeostasis, and inﬂammation. In this review,
we provide a brief update on the different cell death
modalities and describe in more detail the intracellular
crosstalk between survival, apoptotic, necroptotic, and
inﬂammatory pathways that are activated downstream of
death receptors. An important concept is that the different
cell death processes modulate each other by mutual
inhibitory mechanisms, serve as alternative back-up death
routes in the case of a defect in the ﬁrst-line cell death
response, and are controlled by multiple feedback loops. We
conclude by discussing future perspectives and challenges in
the ﬁeld of cell death and inﬂammation research.
Inflammation and cell death: a forced marriage? The oldest
references to inflammation are found on Egyptian papyri dating
from around 1650 BCE. More than 2000 years ago, Celsus (25
BC – c. 50 AD, Rome) described the 4 cardinal signs of inflam-
mation as calor (heat), rubor (redness), tumor (swelling), and
dolor (pain). Although initially considered a passive pathological
consequence of injury characterized by these 4 hallmarks, inflam-
mation has gradually emerged as an active process that initiates at
the site of infection or injury and functions to control infection
and promote tissue repair. Galen of Pergamon (approximately
200 AD) initiated this change of concept by proposing that the
generation of pus is a sign of healing. Rudolf Virchow (1821–
1902, Prussia), founder of the Cell Theory (“Omnis cellula e
cellula”), cellular pathology, and even social medicine, later
referred to such tissue injury as “parenchymatous inflammation”
and introduced the idea that injured tissue can be traced to path-
ological changes intrinsic to the cells themselves. In 1858, he
introduced the notion of cell death as a potential basis for pathol-
ogy through the opposing processes of “necrobiosis,” a physiolog-
ical process of spontaneous wearing out of living parts from
the body, and “necrosis,” an accidental process. Virchow’s necro-
biosis–necrosis dichotomy resembles to some extent the current
apoptosis–necrosis classification.1 Together with the evolving
ideas and molecular insights in inflammation came a shift in our
understanding of the molecular interplay between cell death and
inflammation at the site of tissue injury. Although cell death in
the course of inflammation was initially thought to be a manifes-
tation of tissue damage, it was later recognized as a mechanism of
eliminating pathogens and regulating inflammation by exposing
cellular components or their unique derivatives that attract and
alter the functions of other cells.2
The molecular interplay between inflammation and cell
death is an emerging field of research that is crucial for the
understanding of organismal homeostasis and how these pro-
cesses contribute to a growing list of inflammatory and degener-
ative pathologies. The current notion that both apoptotic and
necrotic cell death is molecularly controlled by defined signaling
mechanisms has increased our interest in the regulatory roles of
cell death in general processes such as development, homeosta-
sis, and inflammation (reviewed elsewhere3). This increased
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understanding is the foundation that allows us to take the first
steps toward therapeutic validation to resolve an excess or lack
of cell death in certain pathologies.4 In this review, we briefly
introduce the different cell death modalities and highlight their
morphological, biochemical, and functional properties. We
describe in more detail the different molecular routes to differ-
ent cell death modalities, focusing on the intracellular crosstalk
between them. We will present evidence that different cell death
processes often modulate each other by mutual inhibitory mech-
anisms, back up each other in the case of defective first-line cell
death responses, and are controlled by multiple feedback loops,
similar to many other cellular processes. This redundancy in cell
death signaling nicely illustrates the plasticity of nature. On one
hand this creates multiple options to induce cell death, but on
the other hand it makes therapeutic targeting and clinical trans-
lation very challenging. We conclude by discussing some current
perspectives and challenges in the field of cell death and inflam-
mation research.
A Snapshot of Cell Death Prototypes
Although the first morphological descriptions of cellular
demise date back to the mid-nineteenth century, the categori-
cal terms “programmed cell death” or “apoptosis” were only
formulated in the late 1960s and early 1970s.5,6 The first mor-
phological classification of cell death was proposed based on
observations in rat embryos exposed to toxicants.7 Today,
these cell death modes are referred to as apoptosis (type I),
autophagic cell death (type II), and necrosis (type III).8 Dur-
ing the 1980s and 1990s apoptosis was found to be genetically
controlled, as was elegantly demonstrated in Caenorhabiditis
elegans (reviewed by Lettre et al.9). Textbooks soon contrasted
apoptosis with necrosis, the latter being considered a purely
accidental and passive cell death. However, the unregulated
nature of necrosis was soon questioned when it was discovered
that tumor necrosis factor (TNF) was able to elicit either the
“classic” features of apoptosis or a “balloon-like” morphology
without nuclear disintegration, depending on the cell type.10
Since then, accumulating evidence has paved the way to the
concept of regulated necrosis.11 Before going into the molecu-
lar details, it is important to note that there are multiple forms
of regulated necrosis (Table 1).3 Below is a brief description of
the best-characterized cell death types.8
Apoptosis and necroptosis
Apoptosis is a caspase-dependent cell death modality. The
proteolytic activation of caspases in apoptotic cells drives cell
rounding, retraction of pseudopodes, reduction of cellular vol-
ume (pyknosis), chromatin condensation, nuclear fragmentation
(karyorrhexis), and plasma membrane blebbing. Even though
there is minimal ultrastructural modification of cytoplasmic
organelles, the cell is systematically dismantled into membrane-
wrapped vesicles (apoptotic bodies) that in vivo are rapidly
engulfed by resident phagocytes, thus preventing exposure of
intracellular components to the immune system. In the absence
of swift clearance by phagocytes, apoptotic bodies undergo sec-
ondary necrosis during which the membrane integrity of the
dead cell corpses is lost. Two distinct pathways regulate apopto-
sis: the extrinsic and intrinsic pathways. The extrinsic pathway
refers to apoptotic cell death triggered by extracellular stress sig-
nals such as damage or pathogen-associated molecular patterns
(DAMPs or PAMPs) or cytokines that are sensed and propagated
primarily by a subset of transmembrane receptors of the tumor
necrosis factor (TNF)-superfamily called death receptors (DR),
Toll-like receptors (TLR) or NOD-like receptors (NLR). Apo-
ptosis induced by the intrinsic pathway occurs in response to a
wide range of intracellular damage or stress signals including
cytokine withdrawal, DNA damage, oxidative stress, endoplasmic
reticulum (ER) stress, and cytosolic Ca2C overload that converge
on mitochondrial outer membrane permeabilization (MOMP)
and the release of mitochondrial factors such as cytochrome C,
Smac/DIABLO, or Omi/HtrA2.12,13 In a cell type-specific fash-
ion, the extrinsic machinery also engages the intrinsic pathway
via processing of BID therefore allowing a proapoptotic amplifi-
cation loop.
Regulated necrosis manifests with similar morphological
features as passive necrosis but death is executed in a cell
autonomous fashion via distinct biochemical processes leading
to cellular rounding followed by swelling (oncosis), cyto-
plasmic granulation, and plasma membrane rupture. Loss of
membrane integrity provokes an inflammatory response by
exposing leaking cellular contents to the immune system.
Regulated necrosis, characterized by oncosis and plasma
membrane permeabilization, includes multiple cell death sub-
classes such as necroptosis, parthanatos, ferroptosis, (n)etosis,
pyroptosis, and ischemia reperfusion injury (IRI)-mediated
necrosis. Each type of regulated necrosis highlights particular
biochemical features, yet it is still unclear whether shared
pathways or converging pathways underline the common
morphological features of these multiple forms of cell death.3
Necroptosis is currently the best-characterized form of regu-
lated necrosis and is mediated by the conserted action of
receptor interacting protein kinase 1 (RIPK1) and RIPK3,
and mixed lineage kinase domain-like (MLKL) in response to
death receptors, Toll- and NOD-like receptors, T-cell recep-
tor, genotoxic stress, and viruses.14-16 The chemical inhibitors
necrostatin-1,17 GSK’843/’87218 and necrosulfonamide
(NSA)19 block necroptosis by respectively inhibiting m/
hRIPK1, hRIPK3, and hMLKL. Of interest is the recently
identified action mechanism of MLKL. The four-helical bun-
dle domain (4HBD) in the N-terminal region of MLKL is
required and sufficient to induce oligomerization, bind phos-
phatidylinositol phosphates, permeabilize membranes, and
induce cell death.20-22 It seems that this membrane permeabi-
lizing activity of 4HBD is controlled by a masking helix H6,
which interacts not only with the helix H2-H5 interface but
also with helix H4 that contains Cys86 (the target of NSA).
Hence it is likely that inhibition by NSA in the liposome
leakage assays that is mediated by covalent modification of
C86 disrupts intra- or intermolecular interactions that are
critical for the formation of pores within the membranes.21
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Other forms of regulated necrosis beyond necroptosis
Mitochondrial permeability transition (MPT)-regulated
necrosis contributes to ischemia reperfusion injury and acute
organ failure. The mitochondrial matrix protein cyclophilin D
(CypD) controls the MPT pore, and opening of the pore leads to
translocation of NADC from the mitochondrial matrix to the
cytosol.3
Ferroptosis involves the production of iron-dependent reac-
tive oxygen species (ROS). Blockade of a cysteine/glutamate anti-
porter that supplies cells with oxidized cysteine suppresses
glutathione biosynthesis. Lipid peroxidation and cell death occur
as a consequence of a decrease in glutathione levels and depletion
of GPX-4.23 A chemical inhibitor of ferroptosis is Ferrostatin-1,
but its molecular target remains unclear.24
The process of parthanatos depends on poly(ADP-ribose)
(PAR) polymerase 1 (PARP1) activation in response to DNA
breakage, ROS, alkylating agents, the Ca2C signaling pathway, or
post-translational modifications such as phosphorylation, acetyla-
tion, or ADP ribosylation.25 The PARylation of proteins is
thought to deplete cells of NADC (and consequently ATP),
resulting in regulated necrosis.3
Pyroptosis is proposed to be a form of regulated necrosis that
typically occurs in specialized immune cells to combat infection.
Pyroptosis is a caspase-1– or caspase-11–dependent cell death
modality that occurs downstream of inflammasome activation
and is typically accompanied by maturation and release of the
cytokines IL-1b and IL-18 as well as other activators of the
immune system.26 Pyroptosis is associated with cellular swelling
and plasma membrane permeabilization, but does not involve
the necroptosis regulators. This highly inflammatory form of cell
death is a defense mechanism against microbial infection and
occurs primarily in infected macrophages and in the dying T cells
of patients with AIDS.27,28
Similar to pyroptosis, NETosis/ETosis also occurs in special-
ized immune cells (such as neutrophils, other granulocytes, and
macrophages) to combat infections. This form of regulated
necrosis is characterized by chromatin decondensation and the
release of (neutrophil) extracellular traps.29 These postmortem
traps are composed of DNA, chromatin, and histones, and enable
immune cells to immobilize and kill bacteria.30 It should be
noted that the release of extracellular traps has also been reported
in the absence of cell death.31
Mutual Interplay Between Cell Death and Gene
Activation
The understanding of death receptor (DR)-mediated signaling
pathways has been at the forefront of many fundamental develop-
ments in cell biology, including the molecular interplay between
apoptosis, regulated necrosis, and inflammatory signaling. There
are 6 human DRs in the TNF superfamily: TNFR1, CD95 (also
known as FAS or APO-1), TRAILR1 (also known as DR4),
TRAILR2 (also known as APO-2, TRICK, DR5, or KILLER),
DR3 (also known as TRAMP or APO-3), and DR6 (reviewed by
Walczak et al.32). These receptors induce death via their
common cytoplasmic death domain (DD). Soon after the discov-
ery of TNF it became clear that the most prominent outcome of
engagement of TNFR1 by this ligand was not cell death, but
instead the induction of cytokines and chemokines. In contrast,
induction of cell death is the dominant consequence of FASL or
TRAIL sensing by their respective receptors. In the case of
TNFR1 signaling, the current model is that sensing of TNF by
TNFR1 induces the assembly of a primary receptor-bound com-
plex that triggers activation of signaling pathways leading to gene
induction. In a subsequent stage, assembly of a secondary
TNFR1-unbound cytosolic complex induces cell death.32 In the
case of FAS and TRAILR1/2, the opposite situation is observed.
Although the receptor-bound primary complex, the death induc-
ing signaling complex (DISC), triggers cell death, the secondary
cytosolic complex regulates gene activation (Fig. 1). The physio-
logic relevance of this sequential signaling is fine-tuning of the
cellular response and provision of an alternative or back-up
response by the secondary cytosolic complex in case the default
pathway activated by the receptor-associated complex fails to
dominate. Pathogens or (epi)genetic factors can interfere with
gene activation or cell death induction. Thus, this sequential sig-
naling probably evolved as a host defense strategy to contend
with pathogens or malicious conditions that may perturb either
pathway.
TNFR1-induced gene activation versus cell death
TNF is a master regulator of inflammation and cell death.
Consequently, signaling downstream of TNFR1 is the best char-
acterized among all DRs. Nuclear factor kappa B (NF-kB)–
mediated gene activation by TNFR1 requires the formation of a
receptor-associated TNFR signaling complex called complex I.33
In brief, cross-linking of TNFR1 by TNF promotes recruitment
of TNF receptor–associated death domain (TRADD) and
RIPK1 to the death domain (DD) of the receptor (Fig. 2). Subse-
quently, TRADD recruits TNF receptor–associated factor 2
(TRAF2), which in turn provides the platform for cellular inhibi-
tor of apoptosis (cIAP)1/2 binding. cIAP1/2 then conjugate com-
ponents of complex I with ubiquitin chains generated from
various types of ubiquitin linkages. These modifications allow
docking of linear ubiquitin assembly complex (LUBAC), which
adds linear ubiquitin chains to NEMO and possibly other com-
ponents of the complex such as RIPK1. The ubiquitin chains
generated by cIAP1/2 and LUBAC enable recruitment and exact
positioning of both the IKKa/IKKb/NEMO and TAB/TAK-
complexes (reviewed by Estornes et al.34). The concerted action
of the latter 2 complexes results in the activation of MAPK and
NF-kB signaling pathways (often referred to as the early signaling
phase) that induce expression of genes encoding prosurvival and
proliferative molecules, cytokines and chemokines, barrier mole-
cules, protease inhibitors, and antioxidants (reviewed by Ben-
Neriah et al.35). Termination of TNF-induced NF-kB activation
requires dismantling of the ubiquitin network of complex I. The
deubiquitylating enzyme USP21 shuts down the early signaling
phase,36 whereas the A20 ubiquitin (Ub)-editing complex,
including TAXBP1/Itch/RNF11 proteins, terminates NF-kB
activation at later phases.37,38 In marked contrast to previous
e975093-4 Volume 2 Issue 4Molecular & Cellular Oncology
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theories, the deubiquitylase activity of A20 was recently demon-
strated to be dispensable for NF-kB termination. Knock-in mice
that express a version of A20 lacking deubiquitylase activity have
no signs of inflammation, possess a normal complement of B, T,
dendritic, and myeloid cells, and undergo normal dynamics of
TNF- and LPS-induced NF-kB activation.39
TNF-induced NF-kB activation drives the expression not
only of inflammatory mediators but also of proteins directly
involved in apoptosis inhibition, such as several Bcl2 family
members, FLICE-like inhibitory proteins (cFLIPs), and cIAPs
(Supplementary Table 1). In accordance with this, mouse
embryonic fibroblasts (MEFs) derived from mice deficient in
components of the NF-kB pathway, such as NEMO, IKKa/b,
p65, or p50/65, fail to upregulate expression of these antiapop-
totic genes and consequently undergo caspase-8–dependent apo-
ptosis following TNF stimulation. Mice deficient in NEMO,
IKKa/b, p65, or p50/65 die at embryonic stage E12-16 as a
result of TNFR1-dependent apoptosis in the liver.40
RIPK1 is a crucial adapter that plays multiple roles within
TNFR1-signaling complexes. RIPK1 ubiquitylation regulates
both TNF-induced NF-kB activation and cell death. The ubiqui-
tin chains conjugated to RIPK1 contribute to recruitment of the
Figure 1. Signaling of death receptors for cell death and survival. (A)The primary response of the inﬂammatory death receptors TNFR1 and DR3 is com-
plex I-mediated gene activation, which is required for a proper inﬂammatory response. (B) The primary response of the prototype death receptors Fas
and TRAILR is induction of cell death. Upon interference with this primary response, for example by pathogens, (epi)genetic factors, or chemical inhibi-
tors, a secondary response prevails. In the case of TNFR1 and DR3 this secondary signal is complex II-mediated cell death (C), whereas gene induction is
typically observed as a secondary signal downstream of Fas and TRAILRs (D). Abbreviations: DR3, death receptor 3; TNFR1, tumor necrosis factor
receptor 1.
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IKKa/b/NEMO complex to the TNFR1 complex I.41 TNF-
induced NF-kB activation therefore fails to proceed efficiently in
cells lacking RIPK1.42-44 The absence of fully defective NF-kB
induction in certain cell types45 probably originates from activa-
tion of alternative mechanisms that compensate for RIPK1 defi-
ciency.46 This “non-essential” role of RIPK1 in TNF-induced
NF-kB activation is supported genetically, as RIPK1-null
embryos survive until birth and therefore do not phenocopy the
early embryonic lethality of mice deficient in the “essential” com-
ponents of the NF-kB pathway, such as p65. Nevertheless,
absence of RIPK1 still sensitizes cells to caspase-8–dependent
apoptosis in response to TNF.42,44,47 These findings were
recently underscored in an in vivo context in which the perinatal
death of RIPK1-deficient mice is triggered, in part, by aberrant
caspase-8 activation.43,48,49 RIPK1 protects cells from caspase-8–
induced apoptosis by contributing to robust antiapoptotic gene
induction as well as by stabilizing cFLIP levels in cells.43 The
idea that the antiapoptotic function of RIPK1 is not limited to
NF-kB activation is supported by an earlier in vitro study that
demonstrated sensitivity of RIPK1-deficient cells to TNF-medi-
ated death even in NF-kB inhibited conditions.50
Paradoxically, in addition its antiapoptotic function, RIPK1
also positively regulates TNF-mediated apoptosis under certain
conditions. In order to understand the induction of apoptosis by
TNF, it is important to discriminate between 2 major conditions:
TNF signaling in the presence of protein translation inhibition
Figure 2. TNFR1 signaling. Upon stimulation with TNF, TNFR1 recruits TRADD and RIPK1, followed by cIAP1, cIAP2, TRAF2, and TRAF5. RIPK1 is then K63-
polyubiquitylated by cIAP1 and cIAP2, which allows docking of the TAK1–TAB2 or TAB3 complex and the IKK complex. Assembly of the IKK complex acti-
vates the NF-kB pathway, which is enhanced by recruitment of the LUBAC through RIPK1 linear ubiquitylation. Subsequently, upon internalization of
TNFR1, RIPK1 is believed to dissociate from the receptor as a result of deubiquitylation by CYLD and interact with FADD, procaspase-8, and FLIPs. The
long isoform of FLIP (FLIPL) and procaspase-8 form a heterodimeric caspase that cleaves and inactivates RIPK1, RIPK3, and CYLD to prevent necroptosis.
This TRADD-dependent complex (also referred to as complex IIa) allows caspase-8 homodimerization and activation, which activates the executioner cas-
pases 3 and 7 resulting in apoptosis. However, when caspase-8 is inhibited by chemical caspase inhibitors or virally encoded proteins such as CrmA or
vIRA, the RHIM domains of RIPK1 and RIPK3 associate in microﬁlament-like complexes called necrosomes. The mutual auto- and transphosphorylation of
RIPK1/3 induces the oligomerization of MLKL, which initiates necroptosis. Upon cIAP inhibition (e.g., by SMAC mimetics) a large TRADD-independent
cytosolic complex is formed between RIPK1, RIPK3, FADD, and the FLIPL/caspase-8 heterodimer, which is referred to as complex IIb. Similar to complex
IIa, RIPK1 and RIPK3 are also inactivated through cleavage by caspase-8/FLIPL heterodimers, apoptosis is induced by release of caspase-8 homodimers,
and necroptosis is induced upon defective caspase-8 function or recruitment. Abbreviations: cIAP, cellular inhibitor of apoptosis; FADD, Fas-associated
death domain; FLIP, FLICE-like inhibitory protein; IKK, inhibitor kB kinase; LUBAC, linear ubiquitin chain assembly complex; RIPK, receptor interacting pro-
tein kinase; RHIM, RIP homotypic interacting motif; MLKL, mixed lineage kinase domain-like; NF-kB, nuclear factor kappa B; SMAC, second mitochondria-
derived activator of caspase; TAB, TAK1 binding protein; TAK, transforming growth factor-b–activated kinase; TNF, tumor necrosis factor; TNFR, tumor
necrosis factor receptor; TRADD, TNF receptor–associated death domain; TRAF, TNF receptor–associated factor; vIRA, viral M45-encoded inhibitor of RIP
activation.
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by cycloheximide (CHX) and that in conditions of cIAP1/2 elim-
ination (obtained by treatment with second mitochondria-
derived activator of caspase [SMAC] mimetics or physiologically
upon activation of certain TNFRs, such as CD40, BAFFR,
TNFRSF12A, and LTbR). When the antiapoptotic NF-kB
response is inhibited by CHX, TNFR1 ligation switches from a
prosurvival to a proapoptotic response. This switch occurs via
internalization of complex I and assembly of complex IIa
(Fig. 2).33 Translation repression promotes caspase-8 activation
by reducing the levels of cFLIP, a relatively unstable endogenous
caspase-8 inhibitor. Under these conditions, RIPK1 deficiency
further sensitizes the cells to death.50,51
The E3 ubiquitin ligase activities of cIAP1/2 are required for
TNF-induced canonical NF-kB activation.52-54 Consequently,
their depletion also induces a switch to caspase-8–mediated apo-
ptosis. Of note, TNF-induced apoptosis in the absence of cIAP1/
2 occurs more rapidly and at a higher rate than that induced
upon single NF-kB inhibition, indicating that cIAP1/2 addition-
ally regulates an NF-kB–independent cell death checkpoint in
the TNFR1.51,55 Interestingly, the excessive death obtained
under these conditions was shown to rely on RIPK1 kinase activ-
ity and not on TRADD (in contrast to complex IIa).51,56 The
RIPK1-containing cytosolic death complex obtained in cIAP1/2-
depleted conditions has been defined as complex IIb to discrimi-
nate it from complex IIa (Fig. 2).34,57 The molecular mechanism
accounting for the differential assembly of complex IIa versus IIb
is poorly understood, but is suggested to rely on the differential
ubiquitylation status of RIPK1 in complex I. Indeed, cIAP1/2
directly conjugates RIPK1 with ubiquitin chains,52,53,58 and
cIAP1/2-mediated RIPK1 ubiquitylation in complex I is believed
to prevent RIPK1 from integrat-
ing complex II.52,56,59 This notion
is supported by the fact that
repression of the RIPK1 deubiqui-
tylase CYLD inhibits recruitment
of RIPK1 to complex IIb.56 Nev-
ertheless, recent studies indicate
that it is probably the proteins
recruited to the ubiquitin chains,
rather than the ubiquitin chains
themselves, that regulate the con-
tribution of RIPK1 to the death
trigger. Indeed, both TAK1 and
NEMO depletion also induce
complex IIb-mediated apoptosis
without affecting RIPK1 ubiqui-
tylation.51,60 Recently, Pellino3
was also found to negatively con-
trol formation of complex IIb in a
NF-kB– and ubiquitin ligase-
independent manner.61
In summary, TNFR1 primarily
induces formation of a membrane-
bound complex that triggers NF-
kB– and MAPK-mediated gene
activation and negatively controls
formation of the cytosolic death inducing complex II. Toggling of
TNFR1-signaling to RIPK1-dependent apoptosis requires a sec-
ondary signal and prevails only upon interference with the primary
signal, for example by depletion of cIAPs, cFLIPL, TAK1, NEMO,
or Pellino3 (Fig. 2).
Fas-induced cell death versus gene activation
Signaling downstream of FAS and TRAILR1/2 also involves
assembly of primary and secondary complexes but the respective
function of these complexes is reversed compared to TNFR1 signal-
ing (Fig. 1). Indeed, the FAS- and TRAILR1/2-associated primary
complex (known as DISC) is composed of the adaptor FADD, cas-
pase-8, and the cFLIP-isoforms, and is responsible for caspase-8–
dependent apoptosis.62 Note that RIPK1 has also been shown to
directly bind to FAS and mediate cell death in the absence of
cIAPs.63,64 This binding seems to be favored mainly when caspases
are blocked.65 A secondary cytosolic gene-activating complex origi-
nates from dissociation of this membrane-bound complex.66,67 In
the case of TRAILR1/2, release of FADD from the DISC triggers
formation of a cytosolic complex II that recruits TRAF2, cIAP1/2,
RIPK1, NEMO, and most likely several other factors to activate
NF-kB, MAPKs, and consequently gene induction.68 In line with
these findings, FAS-induced apoptosis or necroptosis can also be
associated with the production of cytokines and chemokines, which
requires RIPK1 and cIAP1/2 for optimal production.69,70 The che-
motaxis of phagocytes toward apoptotic cells suggests that these
induced factors function as additional “find-me” signals. Interfer-
ence with caspase activation (primary signal) through chemical-70
or pathogen-71 induced inhibition enhances gene activation (sec-
ondary signal). In addition, and contrary to TNFR1 complex I, Fas
Figure 3. Role of FLIP in TNFR1-induced complex II activity. TNFR1 stimulation typically induces NF-kB–medi-
ated survival signaling, for example through upregulation of FLIPL (central panel). Caspase-8/FLIPL hetero-
dimers allow local caspase-8 activity within complex II, resulting in cleavage of RIPK1 and RIPK3. As a result,
apoptosis and necroptosis are inhibited. However, when FLIPL levels are low (for example due to defective
NF-kB activation) active caspase-8 homodimers form, are released from complex II, and induce apoptosis
(left panel). In conditions where FLIPs levels are upregulated, caspase-8/FLIPs heterodimers inhibit local cas-
pase-8 activity, allowing RIPK1/3-mediated necroptosis (right panel). Abbreviations: FLIP, FLICE-like inhibi-
tory protein; NF-kB, nuclear factor kappa B; RIPK, receptor interacting protein kinase; TNFR, tumor necrosis
factor receptor.
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and TRAILR1/2 complex II were also reported to contribute to cell
death under certain conditions by enhancing autocatalytic activa-
tion of caspase-842 or by inducing gene activation (Fig. 1).62,71
Interplay Between Apoptosis and Necroptosis
Induction Downstream of TNFR1
Having outlined the mutual interplay between survival and cell
death signaling downstream of TNFR1 activation, we now describe
the interplay between factors contained within the cytosolic death
complex that dictate the apoptotic or necroptotic outcomes.
Caspase-8/FLIP
Within the death inducing complex II, caspase-8 activity con-
trols apoptotic and necroptotic cell fates. Active caspase-8 sup-
presses necroptosis by cleaving several substrates, including
RIPK1, RIPK3, and CYLD.72-74 CYLD-mediated deubiquityla-
tion of RIPK1 within complex II was reported to facilitate
RIPK1 kinase activation and subsequent necroptosis induction.75
Vice versa, CYLD is downregulated in a TLR-dependent way in
wild-derived mice to protect macrophages from necroptosis.76
The proapoptotic/antinecroptotic function of caspase-8 is regu-
lated by specific interactions with the pseudo-caspase cFLIP.
Whereas caspase-8 homodimers engage apoptosis, caspase-8/
cFLIPL heterodimers suppress both apoptosis and necroptosis.
77
Binding of cFLIPL to caspase-8 throttles caspase-8 activity to pre-
vent apoptosis but allows low levels of enzymatic activity suffi-
cient to cleave and inactivate RIPK1 and RIPK3 (Fig. 3).78 In
cells expressing adequate levels of the pronecrotic kinase RIPK3,
TNF-signaling triggers necroptosis after elimination of this basal
caspase-8 activity.79 In accordance with these findings, the
embryonic lethality of mice deficient in caspase-8 or FADD can
be completely rescued by ablation of RIPK3 or RIPK1 (Supple-
mentary Table 1).80-83 It remains unclear what regulates the dif-
ferent outcomes of caspase-8 homodimer versus caspase-8/cFLIPL
heterodimer activity, but possible mechanisms include differences
in cleavage specificities, access to specific substrates, level of activ-
ity, or subcellular localization.84 Interestingly, caspase-8 heterodi-
merization with an alternative form of cFLIP, cFLIPS, prevents
caspase-8 activity but enhances complex II formation to favor
necroptosis induction (Fig. 3).65,85 Together, these results indi-
cate that the amount of cFLIP in cells protects them from extrin-
sic apoptosis and that the ratio of cFLIPL and cFLIPS isoforms
determines the sensitivity to necroptosis. This spectrum of cell
death regulatory mechanisms is not restricted to TNF signaling
but also operates to control cell fate following DNA damage or
TLR signaling.85,86
RIPK1
The complex role that RIPK1 plays in regulating caspase-8
and RIPK3 was in part revealed by the recent demonstration
that the perinatal lethality of RIPK1-null mice was due to a
combination of aberrant activation of caspase-8 and RIPK3,
such that mice lacking all 3 enzymes survived to adult-
hood.43,48,49 Both cell autonomous and non-cell autonomous
effects contribute to the necessity for RIPK1 for mammalian
life. On one hand RIPK1 is required to prevent apoptosis
induced by TNF, possibly related
to a failure to stabilize and upre-
gulate cFLIPL in response to
TNFR1 signaling. This is recently
underscored by findings that mice
lacking RIPK1 specifically in the
intestinal epithelium developed
severe inflammatory bowel disease
within the first weeks of life due
to extensive caspase-8 mediated
apoptosis, and died as a
result.87,88 On the other hand,
RIPK1 prevents RIPK3-driven
necroptosis promoted by inter-
feron (IFN) and the TLR-adapter
TRIF,43 and possibly other sig-
nals. Since RIPK1 is reported to
be essential for RIPK3 activation
and subsequent necroptosis induc-
tion by TNF, it is surprising to
identify settings where RIPK1
actively suppresses RIPK3.
Whereas RIPK1 is upstream of
RIPK3 for TNF-induced necrop-
tosis, RIPK3 is apical to RIPK1
in TLR- and IFN-induced
Figure 4. Role of RIPK1/3 in TNFR1-induced complex II activity. RIPK1 signals toward survival and cell death
through different functional domains. The adaptor function of RIPK1 is important for activation of MAPK
and NF-kB resulting in cell death inhibition, and has a NF-kB–independent inhibitory action on the forma-
tion of complex IIb. The kinase activity of RIPK1 can be involved in both necroptosis and apoptosis within
complex II. Typically, this occurs under conditions when cIAP1/2 or TAK1 is degraded. RIPK3 is primarily
involved in the induction of cell death. Although its kinase is typically involved in the induction of necropto-
sis, its adaptor function can also contribute to the induction of apoptosis. Abbreviations: cIAP, cellular inhib-
itor of apoptosis; FLIP, FLICE-like inhibitory protein; MAPK, mitogen-activated protein kinase; NF-kB, nuclear
factor kappa B; RIPK, receptor interacting protein kinase; TAK, transforming growth factor-b–activated
kinase; TNFR, tumor necrosis factor receptor.
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necroptosis. In the context where the ordering of kinases is
reversed, RIPK1 may function as an adapter to bridge RIPK3
to the necroptosis suppressive activity of caspase-8, and in the
absence of RIPK1 developmental cues might drive lethal levels
of RIPK3 activity. The dynamic interplay and interdependence
of these complex II components confers a crucial host defense
function to limit pathogen spread, especially upon interference
or perturbation of any one of these processes.89,90 This might
explain why this complex interrelationship exists and why abla-
tion of specific elements (such as RIPK1, FADD, caspase-8,
and cFLIP) pushes the system to lethality. In line with this rea-
soning, the tissues most affected by disruption of these gene
products (intestine, lung, skin, endothelium, hematopoietic
cells) represent crucial barriers to infection that are constantly
engaged by pathogens.91
The central role of RIPK1 kinase activity in deleterious TNF
signaling was recently revealed genetically by the generation of
RIPK1 kinase dead knock-in mice.49,92-94 In contrast to RIPK1-
null mice, which die within a few days after birth, RIPK1 kinase
dead knock-in mice are viable and fertile, demonstrating that the
vital role of RIPK1 following mammalian parturition is due to
RIPK1 adapter function rather than enzymatic activity. Never-
theless, mice expressing a kinase dead mutant of RIPK1 were
completely resistant to TNF-induced shock and, as anticipated,
cells derived from these mice were protected from TNF-induced
cell death (Fig. 4).49,92-94 In addition, RIPK1 kinase activity was
dispensable for MAPK and NF-kB activation, indicating that
apoptosis/necroptosis mediated by RIPK1 enzymatic activity is
probably the dominant driver of TNF-shock rather than primary
gene induction.
Mice lacking Sharpin, a component of the LUBAC complex,
develop a lethal inflammatory skin phenotype within 12 weeks of
age and also manifest multiorgan inflammation. This severe
TNF-mediated inflammatory phenotype is absent in Sharpin
mutant mice bred on a RIPK1 kinase dead background, demon-
strating the central role of aberrant RIPK1 kinase activity in this
animal model.92 Together, these findings clearly demonstrate a
tissue-specific requirement for RIPK1 kinase activity upstream of
both caspase-8 and RIPK3 in promoting inflammation. Of note,
patients with mutations in HOIL, another LUBAC component,
also develop severe autoinflammation that is probably driven by
RIPK1 kinase activity.95 It will be important to evaluate whether
a deficiency in RIPK1 kinase activity also rescues the lethal phe-
notype of mice deficient in cIAP1/2, FADD, caspase-8, or cFLIP,
which succumb at E10.5 due to TNF-induced necroptosis and
apoptosis, and of mice deficient in p65, IkB, IKKb, NEMO, or
TAB2, which die later in gestation due to TNF-induced liver
apoptosis. Thus, as a key regulator of inflammation, apoptosis,
and necroptosis, RIPK1 is positioned at a strategic crossroads of
multiple signaling nodes in the inflammatory response and must
be tightly regulated to ensure normal tissue homeostasis.
RIPK3
Although RIPK3 knockout mice are viable and fertile,
RIPK3 D161N kinase dead knock-in mice die at embryonic
day E10.5 due to massive levels of apoptosis in the embryo
and yolk sac vasculature. This embryonic death is rescued by
ablation of RIPK1 or caspase-8, indicating that RIPK3 can
itself engage both RIPK1 and caspase-893 and suggesting that
RIPK3 kinase activity is essential in embryos to prevent aber-
rant complex II formation and lethal apoptosis. It remains
unclear at the structural level why D161N kinase-dead
RIPK3 is proapoptotic, though it is likely that the kinase
domain functionally “masks” the RIP homotypic interacting
motif (RHIM) to prevent spurious activation.96 In this sce-
nario, D161N alters the conformation of RIPK3 such that
the RHIM is exposed for binding to RIPK1 to initiate apo-
ptosis. This model predicts that the kinase and RHIM
domains collaborate to control scaffolding of the necroptotic
and apoptotic machineries. Whereas TNF signaling typically
requires RIPK1 to activate RIPK3 to induce necroptosis, it
has been noted that TNF can trigger RIPK3 activation even
in the absence of RIPK1 if RIPK3 levels are induced to high
levels in cells (Fig. 4).97 In the absence of RIPK1 and the
presence of elevated levels of RIPK3, TNF can activate
RIPK3 to induce cell death by both a caspase-8–dependent
mechanism and a caspase-independent mechanism.51,97 More-
over, RIPK3 has also been reported to positively contribute
to full caspase-8 activation downstream of TNFR1 indepen-
dently of its kinase activity or intact RHIM in conditions of
RIPK1-dependent apoptosis.51 Finally, similar to depletion of
RIPK1,44,47 blocking TNF-induced necroptosis by suppress-
ing RIPK3 or MLKL toggles the cell death response to apo-
ptosis, albeit with different kinetics.98 Collectively, these
studies indicate that the precise control of the complex II
machinery is necessary to prevent a lethal imbalance of nec-
roptotic or apoptotic pathways.
Emerging Insights in Pathogen-Cell Death
Interactions
Considering the crucial role of DRs in homeostasis and their
therapeutic impact (for example, anti-TNF drugs such as
Enbrel, Remicade, Humira, Cimzia, and Simponi), most
of our molecular understanding of cell fate originates from DR-
focused research. However, new exciting fields that are intercon-
nected with cell death beyond DRs are now being explored. In
this respect, we are beginning to pinpoint bottlenecks or converg-
ing nodes in cell death signaling that can be therapeutically
explored. In particular, much insight has been gained through
the study of pathogens, such as herpes virus, that have evolved
mechanisms to evade cell death defenses over 100 million years.
A prototype example is cytomegalovirus (CMV), which sup-
presses caspase-8-induced apoptosis and RIPK3-induced necrop-
tosis through genes encoding vICA and vIRA respectively
(reviewed extensively elsewhere71,90). These findings provide key
insights into how inhibition of caspase-8 by a viral gene unleashes
RIPK3-mediated necroptosis that is in turn suppressed by a
counter adaptation to close the antiviral necroptotic trap door
(see Mocarski et al. for more extended reading99).
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Concluding Perspectives
Intense research on inflammation and cell death indicates that
regulated necrosis is an important cause or catalyst of several
common diseases,4 putting cell death research once more in the
center stage. Current therapeutic strategies mainly focus on inhi-
bition of the kinase activity of RIPK1 and RIPK3. Until recently,
RIPK3 inhibitors were predicted to be superior over RIPK1
inhibitors because necroptosis occurs in the absence of RIPK1,
but not in the absence of RIPK3, in response to some stim-
uli.79,97,100 However, the lethal phenotype of the RIPK3 D161N
kinase dead knock-in mice combined with the capacity of small-
molecule inhibitors of RIPK3 to spontaneously induce apoptosis
suggest that pharmacologic targeting of RIPK3 will remain a
challenge.18 RIPK1 kinase-deficient mice, however, reveal no
spontaneous phenotype and retain the ability to activate NF-kB
and MAPK pathways despite a defect in both apoptotic and nec-
roptotic cell death.49,92-94 These findings have re-energized inter-
est in targeting the kinase function of RIPK1. Additionally,
RIPK1 kinase inhibition may preserve beneficial inflammation
while preventing the deleterious outcomes of inflammation,
which might enhance its therapeutic impact. Alternatively, small
molecules that disrupt RHIM signaling could also be effective at
preventing cell death but so far such molecules have remained
elusive.
A reviving field, originally recognized by Virchow, is the close
interconnection between cell death and inflammation. This is
emphasized by some recent findings that classic cell death inducers
such as caspase-8 and RIPK3 seem to act upstream of inflamma-
some activation in a cell autonomous way.101-106 However, the
mechanisms of this connection remain unclear. RIPK1, RIPK3,
and other complex II components have all been implicated in the
regulation of inflammation although uncoupling these functions
from their roles in cell death remains a challenge. This could
imply that inducers of the classic prototypic cell death types of
apoptosis and necroptosis are involved in the switch to more pro-
fessional cell death mechanisms, such as pyroptosis and maybe
also (N)ETosis, as a defense strategy against pathogens. Clarifying
the latter issue will be very important in the light of current thera-
peutic strategies to explore the potential of blocking necrosome
functioning in an attempt to interfere with degenerative diseases.
Despite recent advances in our understanding of inflamma-
tion, apoptosis, necroptosis, and their entwined relationships,
many unanswered questions still need to be addressed. An
intriguing aspect that requires further clarification is the NF-
kB–independent inhibitory action of complex I members in
repressing complex II activation. RIPK1, TAK1, NEMO, and
TAB2 were proposed as candidates that directly control com-
plex II formation or activity. In particular, the fact that
TAB2-deficient mice do not show a phenotype on NF-kB
activation107 yet die from massive liver apoptosis similar to
mice deficient in p65, IKKb, TAK1, or NEMO mice remains
intriguing and incompletely understood. Moreover, the rescue
of RIPK1 kinase dead mutant mice from both TNF-induced
shock and the lethal TNF-induced inflammation in Sharpin
mutant mice call into question the dominance of NF-kB and
MAPK activation in deleterious inflammation and suggest that
RIPK-kinase dependent processes including both apoptosis
and necroptosis may be the major TNF-signaling outputs con-
tributing to diseases caused by this master regulator.
What exactly triggers the conversion of complex I to com-
plex II? Is it internalization, deubiquitylase activity, or still
unidentified mechanisms? The proposed role of CYLD in the
transition of complex I to II56 has recently been questioned;
instead, CYLD function was proposed to act mainly within
complex II itself.75 There is accumulating evidence that inter-
nalization is required to allow the induction of cell death,108-
110 which would imply subsequent formation of complex II.
The recent findings that mice deficient in ceramide synthase
2 are completely protected against lipopolysaccharide/Gal-
induced hepatic liver failure due to defect TNFR internaliza-
tion108 and that viruses interfere with DR internalization to
block cell death induction109 re-enforce the central role of
internalization in the induction of cell death. It would be
interesting to analyze the formation of complex II in cells
deficient in TNFR internalization to clarify this issue. Alter-
natively, considering that depletion of IAPs by SMAC mim-
etics triggers complex II formation in some cells independent
of TNF-signaling, and thus complex I, the cytosolic complex
II may form sequentially and not as a direct maturation of
complex I.
In conclusion, the mutual negative interplay between cell
death pathways nicely illustrates the integration of biological pro-
cesses. One trigger initiates a spectrum of competing signals.
This signaling cross talk provides the capacity to survey transduc-
tion and provide alternative outcomes to contend with situations
such as interference by pathogens. Unraveling these highly inter-
connected host defense networks will remain a challenge but
should provide a path forward for the treatment of inflammatory
disease. Although this review has focused primarily on the rela-
tionship between apoptosis and necroptosis, further efforts will
likely unveil unexpected connections to other cell death processes
such as autophagy, organelle stress, lipid metabolism, and senes-
cence, and provide insights into the design of therapeutic strate-
gies that can target “bad” inflammation while preserving “good”
inflammation.
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